The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort-Reference-Cited by-同舟云学术

The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort

Published:2022-12-02 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Ferriero Mariaconsiglia^ORCID,Prata Francesco^ORCID,Mastroianni Riccardo,De Nunzio Cosimo^ORCID,Tema Giorgia,Tuderti Gabriele,Bove Alfredo Maria^ORCID,Anceschi Umberto,Brassetti Aldo^ORCID,Misuraca Leonardo,Giacinti Silvana,Calabrò Fabio,Guaglianone Salvatore,Tubaro Andrea,Papalia Rocco,Leonardo Costantino,Gallucci Michele,Simone Giuseppe^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-022-00623-5.pdf

Reference33 articles.

1. Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Bergman AM, van Moorselaar RJA, et al. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. Prostate Cancer Prostatic Dis. 2021;24:871–9.

2. Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, et al. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018;36:3251–8.

3. Cornford P, van den Bergh RCN, Briers E, van den Broeck T, Cumberbatch MG, de Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82.

4. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080–7.

5. Mori K, Miura N, Mostafaei H, Quhal F, Sari Motlagh R, Pradere B, et al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2020;23:539–48.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCAN Podcast Episode 3: Dr Ferriero and local treatments in mCRPC;2024-02-25

2. Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort;Cancers;2023-09-29

3. Aptamer guided nanomedicine strategies in prostate cancer: Targeting and diagnosis;Journal of Drug Delivery Science and Technology;2023-08

4. The Impact of Metastasectomy on Survival Outcomes of Renal Cell Carcinoma: A 10-Year Single Center Experience;Cancers;2023-06-25

5. Radical prostatectomy findings in patients with locally aggressive Grade group 5 prostatic adenocarcinoma and negative limited or extended pelvic lymph node dissection;Pathology - Research and Practice;2023-04